Choose a language and wait for the translated text.
The hearing is part of a broader push launched in April, when Trump ordered the U.S. Food and Drug Administration to focus on qualifying psychedelic drug programs for its priority-voucher program.
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace | PharmaVoice
